BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Plexpress and Admescope Expand TRACPACK ADME-Tox Screening Services


11/5/2012 12:08:38 PM

HELSINKI, FINLAND, 5 November 2012: Plexpress, developer of the innovative TRAC platform for high-throughput gene expression analysis, has announced plans to extend its collaboration with the contract research organization (CRO), Admescope. The new TRACPACK INDUCTION Screening Service is optimized for screening high priority drug candidates, producing all the data required to meet FDA regulations. This involves using hepatocytes from three separate donors and generating both CYP mRNA expression and protein activity measurements. For the earlier screening of interesting compounds, the TRACPACK CYP+ mRNA Screening Service is a predictive tool that allows compounds to ‘fail early’ before significant time and resources have been utilized. To facilitate rapid and cost-effective screening this is targeted towards mRNA expression analysis only, analyzing key marker genes for drug transport, toxicity and phase II drug metabolism.

Dr. Jari Rautio, CEO of Plexpress, said: “TRAC is proving highly attractive tool for ADME-Tox related mRNA studies thanks to the numerous cost, time and accuracy benefits it offers when compared to traditional approaches such as qPCR. This interest has also likely been fueled by recent recommendations from the FDA, which suggest that measuring CYP mRNA levels provides the best way to assess drug effectiveness and tolerability (1). Combining high sample throughput with gene multiplexing to increase assay speed while minimizing technical variation, TRAC has the power to significantly boost efficiency in the laboratories of both CROs and Pharma.”

Dr. Ari Tolonen, CEO & CSO of Admescope, commented: “To more effectively meet the needs of our customer’s drug screening programs, we have diversified our ADME-Tox offering to provide both rapid early screening and in-depth analysis.” The TRACPACK-CYP+ mRNA process involves exposing HepaRG cells to a number of test compounds, at different concentrations in technical triplicate, for 24-48 hours. For added reliability, positive control inducers are also included. Following exposure, the cells are lysed in Plexpress’ proprietary TRAC lysis buffer and subjected to gene expression analysis using pre-validated TRAC panels containing up to 30 genes. These include members of the CYP family, providing a reliable indication of drug metabolism, toxicity, transport and efficacy.

TRACPACK INDUCTION expands upon the data offered by the previous service including CYP enzyme activity assays. The enhanced service also increases the number of cell donors to three, maximizing the biological relevance of the results generated and to fulfill FDA requirements. In this way, TRACPACK INDUCTION provides a single, integrated service for all CYP induction analysis, ensuring consistent and reliable data. All TRACPACK results are delivered to the customer electronically, in an easy-to-use, summarized format that makes further data analysis fast and easy.

For more information on the updated TRACPACK-CYP+ mRNA and TRACPACK INDUCTION Screening Services, please visit the Admescope website. For more information on TRAC targeted gene expression analysis visit www.plexpress.com. Reference:

1. FDA Guidance for Industry Report (Feb 2012): Drug Interaction Studies Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations

About Plexpress

Plexpress was established as a spinoff from the Finnish Technology Research Center VTT in 2007. Including R&D at VTT, the company’s TRAC technology has been developed continuously for nearly 10 years and it has been documented in over 15 publications. The technology was originally developed for demanding bioprocess applications, which required a very robust solution for gene expression analysis. Since starting operations in 2008, the company has carried out over 50 projects using the TRAC technology in the fields of pharmaceutical development and academic research.

For further information see: www.plexpress.com

About Admescope

Admescope Ltd is an ADME CRO located in Oulu, Finland. The Admescope team has planned and conducted more than 800 ADME-related research projects for a high number of European biotech & pharma companies, and has published about 80 scientific papers in the field. The key expertise of the Admescope team centres around in vitro & in vivo drug metabolism, including metabolite profiling & identification using various LC/MS based techniques, drug-drug interactions and quantitative bioanalysis.

For further information see: http://www.admescope.com/



Read at BioSpace.com

Plexpress
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->